Lazard Asset Management
SNDX icon

Lazard Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Lazard Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,140
Closed -$297K – 2067
2025
Q4 		$297K Buy
+14,140
New +$247K ﹤0.01% 1535
2025
Q3 		– Sell
-7,142
Closed -$66K – 2274
2025
Q2 		$66K Buy
+7,142
New +$78.6K ﹤0.01% 1962
2025
Q1 		– Sell
-11,602
Closed -$153K – 2564
2024
Q4 		$153K Buy
+11,602
New +$199K ﹤0.01% 1686
2022
Q2 		– Sell
-4,040
Closed -$70K – 2554
2022
Q1 		$70K Buy
4,040
+26
+0.6% +$438 ﹤0.01% 1566
2021
Q4 		$87K Buy
+4,014
New +$74.2K ﹤0.01% 1495

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Lazard Asset Management's SNDX Position: Q1 2026 in Review

Lazard Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 14,140 shares — an estimated $297K sold.

Lazard Asset Management first reported a position in SNDX in Q4 2021 and held it in 5 quarters. The position peaked at $297K in Q4 2025. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Lazard Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 14,140 Syndax Pharmaceuticals shares in Q1 2026, an estimated $297K.
  • Lazard Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Lazard Asset Management's Syndax Pharmaceuticals position peaked at $297K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.